Cell and gene therapies bring a level of complexity that puts analytical capabilities at the center of development. Characterizing living and highly variable products, developing potency assays, establishing release testing, and maintaining comparability through process changes all shape how quickly and confidently a program can advance.
Building an analytical strategy alongside the manufacturing process can help sponsors reduce risk, support regulatory expectations, and prepare for the demands of later-stage and commercial supply. In this edition of the Outsourced Pharma Capabilities Update (OPCU), hear from CDMOs and service providers addressing key considerations across cell and gene therapy development and analytical services, from process development and characterization to method validation and quality control. Watch the presentations below for perspectives on aligning analytics and manufacturing to support your program’s progress.
Recent Sessions Available On-Demand
AI Drug Manufacturing & Viral Vectors – October 2026
mRNA & Packaging, Labeling & Logistics – October 2026
Fill/Finish – October 2026
ADC – October 2026
Upcoming OPCU Topics & Times
Enabling ADC Success | 12/1/2026, PM Session
Mastering Aseptic Fill-Finish | 12/1/2026, PM Session
Access more on-demand OPCU recordings and upcoming sessions here.